MedTrace Logo

A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia

NCT02434497 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2018-02-27

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the safety of Rosuvastatin in Children and Adolescents with Homozygous Familial Hypercholesterolemia.

Conditions

  • Homozygous Familial Hypercholesterolemia (HoFH)

Interventions

DRUG

Rosuvastatin 20mg

Active drug 1 or 2 tablets will be taken taken orally, QD, either in the morning or in the evening

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-06
Primary Completion
2016-11-17
Completion
2016-11-17

Countries

  • Belgium
  • Canada
  • Denmark
  • Israel
  • Malaysia
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02434497 on ClinicalTrials.gov